Express Mail Mailing Label No. EV926974370US



PATENT Attorney Docket No. WYE-031

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Martinez et al. CONFIRMATION NO.: 2977

SERIAL NO.: 10/751,736 GROUP NO.: 1642

FILING DATE: January 6, 2004 EXAMINER: Yao, Lei

TITLE: Compositions and Methods for Diagnosing and Treating Colon Cancers

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) above but before the mailing date of any of a final action under 37 C.F.R. 1.113, a notice of allowance under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein; or

Supplement Serial No.: Page 2 of 2	10/751,7	nation Disclosure Statement 36						
	(3)	after the period defined in (2) above but before the payment of the issue fee, AND						
		the requisite Statement is below, AND						
	the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is							
	•	fully requested that each of the patents and publications listed on the attached Form other information contained herein, be made of record in this application. Respectfully submitted,						
Date: Jan Reg. No.: Tel. No.: Fax No.:	48,645 (617) 2	Brian A. Fairchild, Ph.D. Attorney for Applicants Kirkpatrick & Lockhart Preston Gates Ellis LLP						

BOS-1043537 v1



Express Mail Mailing Label No. EV926974370US

SHEET 1 OF 1

FORM PTO - 1449 SUPPLEMENTAL				ATTORNEY DOCKET NO.: WYE-031										
				APPLICANT(S):					Martinez, et al.					
INFORMATION DISCLOSURE STATEMENT					SERIAL NO.:					10/751,736				
					FILING DATE:					January 6, 2004				
						GROUP NO.: 1642							_	
			U.S.	PATE	ENT DO	CUMEN	TS					-		
EXAM. INIT.		DOCUMENT NUMBER DA		NAME			CLASS		SUB CLASS		FILING DATE IF APPROPRIATE			
	Al	US 2004/0005313A1	01/08/2004	4 (Clevers e	t al.						07/16/2002		
			FOREIC	GN PA	TENT	DOCUM	IENTS	S						
EXAM. INIT.		DOCUMENT NUMBER	DATE	COL	INTRY DE	ĆLASS	!		1		ABSTRACT ONLY		ENGLISH LANG (Y/N)	
	Bl	WO 2004/005457 A2	01/15/2004	wo				0.	07/08/2003		N		Y	
	B2	WO 2004/040828 A2	05/13/2004	wo				10	10/30/2003		N		Y	
	ВЗ	WO 2004/074436 A2	09/02/2004	WO				02	02/11/2004		N		Y	
	B4	WO 2004/098521 A2	11/18/2004	wo						8/2004 N			Y	
	B5	EP 1 602 930 A2	12/07/2005	EP						20/2004 N			N	
	1		OTHER AR	T, JO	URNA	L ARTIC	LES,	ETC.					l	
EXAM. INIT.														
	CI	European Search Re	port dated M	larch 1	17, 2006	5, 7 pages.								
	C2	C2 McClanahan <i>et al.</i> , "Identification of Overexpression of Orphan G Protein-Coupled Receptor GPR49 in Human Colon and Ovarian Primary Tumors," <u>Cancer Biology & Therapy</u> , 5(4):419-426, April 2006.												
	C3 Yamamoto <i>et al.</i> , "Overexpression of Orphan G-Protein-Coupled Receptor, <i>Gpr</i> 49, in Human Hepatocellular Carcinomas with β-Catenin Mutations," <u>Hepatology</u> , 37(3):528-533, March 2003.										03.			
EXAMI	NER				DATE CONSIDERED									